Safety and immunogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian children

References

• O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T, Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374:893 - 902; http://dx.doi.org/10.1016/S0140-6736(09)61204-6; PMID: 19748398
   PubMed Web of Science ®Google Scholar
• Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, Muenz LR, O’Brien KL. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010; 7:7; http://dx.doi.org/10.1371/journal.pmed.1000348; PMID: 20957191
   PubMed Web of Science ®Google Scholar
• Alliance GAVI. Target Product Profile (TPP) for the pneumococcal AMC: master table [Internet]. GAVI Alliance; 2008 Dec 18 [cited 2013 July 31]. Available from: http://www.gavialliance.org/funding/pneumococcal-amc/about/.
   Google Scholar
• Alliance GAVI. Countries approved for support - results & evidence [Internet]. GAVI Alliance; 2013 March [cited 2013 July 31]. Available from: http://www.gavialliance.org/results/countries-approved-for-support/.
   Google Scholar
• Falade AG, Lagunju IA, Bakare RA, Odekanmi AA, Adegbola RA. Invasive pneumococcal disease in children aged <5 years admitted to 3 urban hospitals in Ibadan, Nigeria. Clin Infect Dis 2009; 48:Suppl 2 S190 - 6; http://dx.doi.org/10.1086/596500; PMID: 19191615
   PubMed Web of Science ®Google Scholar
• Jarju S, Baldeh FB, Dione MM, Kwambana B, Ba M, Sonko MA, Hama KM, Aminata GA, Francois H, Basile AG, et al. Potential serotype coverage of PCV-13 against pneumococcal meningitis in West Africa. Poster session presented at 8th International Symposium on Pneumococci and Pneumococcal Diseases; 2012 Mar 11-15; Iguaçu Falls, Brazil.
   Google Scholar
• Adetifa IM, Antonio M, Okoromah CA, Ebruke C, Inem V, Nsekpong D, Bojang A, Adegbola RA. Pre-vaccination nasopharyngeal pneumococcal carriage in a Nigerian population: epidemiology and population biology. PLoS One 2012; 7:e30548; http://dx.doi.org/10.1371/journal.pone.0030548; PMID: 22291984
   PubMedGoogle Scholar
• Greenberg D, Givon-Lavi N, Newman N, Bar-Ziv J, Dagan R. Nasopharyngeal carriage of individual Streptococcus pneumoniae serotypes during pediatric pneumonia as a means to estimate serotype disease potential. Pediatr Infect Dis J 2011; 30:227 - 33; http://dx.doi.org/10.1097/INF.0b013e3181f87802; PMID: 20861756
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, November 2011 – conclusions and recommendations. Wkly Epidemiol Rec 2012; 87:1 - 16; PMID: 22242233
   PubMedGoogle Scholar
• Dicko A, Odusanya OO, Diallo AI, Santara G, Barry A, Dolo A, Diallo A, Kuyinu YA, Kehinde OA, François N, et al. Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial. BMC Public Health 2011; 11:882; http://dx.doi.org/10.1186/1471-2458-11-882; PMID: 22112189
   PubMed Web of Science ®Google Scholar
• Forsgren A, Riesbeck K, Janson H. Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Clin Infect Dis 2008; 46:726 - 31; http://dx.doi.org/10.1086/527396; PMID: 18230042
   PubMed Web of Science ®Google Scholar
• Prymula R, Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev Vaccines 2009; 8:1479 - 500; http://dx.doi.org/10.1586/erv.09.113; PMID: 19863240
   PubMed Web of Science ®Google Scholar
• Lagos RE, Muñoz AE, Levine MM, Lepetic A, François N, Yarzabal JP, Schuerman L. Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children. Hum Vaccin 2011; 7:511 - 22; http://dx.doi.org/10.4161/hv.7.5.14634; PMID: 21441782
   PubMed Web of Science ®Google Scholar
• Silfverdal SA, Prymula R, Traskine M, Habib A, Borys D, Schuerman L. Immunogenicity/reactogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) during fourth year of life. Poster session presented at: 8th International Symposium on Pneumococci and Pneumococcal Diseases; 2012 Mar 11-15; Iguaçu Falls, Brazil.
   Google Scholar
• Vesikari T, Karvonen A, Korhonen T, Karppa T, Sadeharju K, Fanic A, Dieussaert I, Schuerman L. Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of age. Pediatr Infect Dis J 2011; 30:e130 - 41; http://dx.doi.org/10.1097/INF.0b013e31821d1790; PMID: 21540760
   PubMed Web of Science ®Google Scholar
• Prymula R, Habib A, François N, Borys D, Schuerman L. Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamol. Vaccine 2013; 31:2080 - 8; http://dx.doi.org/10.1016/j.vaccine.2013.01.044; PMID: 23391599
   PubMed Web of Science ®Google Scholar
• Prymula R, Siegrist CA, Chlibek R, Zemlickova H, Vackova M, Smetana J, Lommel P, Kaliskova E, Borys D, Schuerman L. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009; 374:1339 - 50; http://dx.doi.org/10.1016/S0140-6736(09)61208-3; PMID: 19837254
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Saez-Llorens X, Lopez P, Abate H, Smith E, Posleman A, Cortes-Barbosa C, Ceballos A, Tregnaghi M, et al. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) against invasive pneumococcal disease in Latin America. Poster Session presented at 9th International Symposium on Antimicrobial Agents and Resistance (ISAAR); 2013 Mar 13-15; Kuala Lumpur, Malaysia.
   Google Scholar
• Saez-Llorens X, Castrejon MM, Rowley S, Wong D, Calvo A, Rodriguez M, Troitino M, Lommel P, Hausdorff WP, Borys D, et al. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) against acute otitis media in children in Panama. Paper presented at 9th International Symposium on Antimicrobial Agents and Resistance (ISAAR); 2013 Mar 13-15; Kuala Lumpur, Malaysia.
   Google Scholar
• Tregnaghi MW, Sáez-Llorens X, Lopez P, Abate H, Smith E, Posleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, et al. Efficacy of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) against community-acquired pneumonia in children from Latin America: a randomized controlled trial. Paper presented at XV Congresso Latino Americano Infectologia Pediátrica – SLIPE; 2013 Jun 26-29; Sao Paulo, Brazil.
   Google Scholar
• Bermal N, Szenborn L, Edison A, Hernandez M, Pejcz J, Majda-Stanislawska E, Gatchalian S, Fanic A, Dieussaert I, Schuerman L. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV/Hib and poliovirus vaccines. Pediatr Infect Dis J 2011; 30:69 - 72; http://dx.doi.org/10.1097/INF.0b013e3181f2da06; PMID: 20980933
   PubMed Web of Science ®Google Scholar
• Nunes MC, Madhi SA. Review on the immunogenicity and safety of PCV-13 in infants and toddlers. Expert Rev Vaccines 2011; 10:951 - 80; http://dx.doi.org/10.1586/erv.11.76; PMID: 21806394
   PubMed Web of Science ®Google Scholar
• Lalwani S, Chatterjee S, Chhatwal J, Verghese VP, Mehta S, Shafi F, Borys D, Moreira M, Schuerman L. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study. Hum Vaccin Immunother 2012; 8:612 - 22; http://dx.doi.org/10.4161/hv.19287; PMID: 22634448
   PubMed Web of Science ®Google Scholar
• Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001; 8:266 - 72; PMID: 11238206
   PubMedGoogle Scholar
• Henckaerts I, Goldblatt D, Ashton L, Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 2006; 13:356 - 60; http://dx.doi.org/10.1128/CVI.13.3.356-360.2006; PMID: 16522777
   PubMed Web of Science ®Google Scholar
• Poolman JT, Frasch CE, Käyhty H, Lestrate P, Madhi SA, Henckaerts I. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol 2010; 17:134 - 42; http://dx.doi.org/10.1128/CVI.00289-09; PMID: 19889940
   PubMed Web of Science ®Google Scholar
• Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, Keyserling HL, Carlone GM. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997; 4:415 - 22; PMID: 9220157
   PubMedGoogle Scholar
• Henckaerts I, Durant N, De Grave D, Schuerman L, Poolman J. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 2007; 25:2518 - 27; http://dx.doi.org/10.1016/j.vaccine.2006.09.029; PMID: 17034907
   PubMed Web of Science ®Google Scholar